
Alveo and Royal GD Partner for Rapid Animal Diagnostics
Alveo Technologies and Royal GD have announced a long-term partnership to expand their joint offerings in rapid molecular diagnostics for animal health, announced in a press release. Their first co-developed product, the Alveo Sense™ Poultry Avian Influenza test, was introduced in the EU in late 2024 and is now expanding into the Middle East and Northern African markets.
The partnership aims to meet the growing demand for rapid, portable diagnostics by focusing on the co-development and distribution of products across multiple species, including poultry, cattle, swine, and equine. Royal GD will serve as a development and global distribution partner for the Alveo Sense Poultry Avian Influenza test, which has already been validated for the Middle East market.
The Alveo Sense test detects and differentiates between Avian Influenza Type A, H5, and H7 or H9 with over 99% specificity and 98.3% sensitivity for H5. It provides results in under 45 minutes using cloacal and oropharyngeal samples, with data uploaded to the cloud for real-time insights into viral outbreaks.
This partnership addresses critical needs in animal health by providing rapid diagnostics that eliminate lab bottlenecks and offer near real-time data to stakeholders, enhancing disease control measures and food supply safety.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.
Also, consider following our LinkedIn page AI Brief.
More from: Healthcare & Life Sciences
Subscribe to Daily AI Brief
Daily report covering major AI developments and industry news, with both top stories and complete market updates